A sugar‐coated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD‐19

L. Steinman

The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody. The targeted therapy specifically blocks the antibody from binding to a particular sugar on the myelin sheath. The authors’ findings are applicable to a parallel strategy for the generation of polysaccharides similar to those present in the receptor‐binding domain of CoViD‐19, which might inhibit viral adhesion to its receptor and thus lead the way toward vaccines.

Read the highlighted article on page 486 and the full Editorial Highlight on page 465.

中文翻译：

---

发行信息

糖衣疗法可以治疗罕见的神经系统疾病，为诱饵聚糖治疗提供了蓝图，并为CoViD-19提供了潜在的疫苗

斯坦曼

本社论着重介绍了Aliu及其同事进行的一项研究，该研究题为“通过抗原特异性糖多聚体选择性抑制抗MAG IgM自身抗体与髓磷脂结合”，该研究发表在《神经化学杂志》上。高度特异性的靶标可治疗罕见的神经系统疾病，其中髓鞘的碳水化合物成分受到抗体的攻击。靶向疗法可特异性阻止抗体与髓鞘上的特定糖结合。作者的发现适用于与CoViD-19受体结合域中存在的多糖相似的平行产生多糖的策略，这可能会抑制病毒与其受体的粘附，从而为疫苗铺平道路。

阅读第486页的突出显示的文章和第465页的完整社论集锦。